ABSTRACT
Poly(ethylene glycol) (PEG) conjugates of Dicer-substrate small interfering RNA (DsiRNA) have been prepared to investigate a new siRNA release strategy. 3'-sense or 5'-antisense thiol-modified, blunt-ended DsiRNAs, inhibiting enhanced green fluorescent protein (eGFP) expression, were covalently conjugated to PEG with varying molecular weights (2, 10, and 20 kg/mol) through a stable thioether bond using a Michael addition reaction. The DsiRNA conjugates with 2 kg/mol PEG (both 3'-sense or 5'-antisense strand conjugated) and the 10 kg/mol PEG conjugated to the 3'-sense strand of DsiRNA were efficiently cleaved by recombinant human Dicer to 21-mer siRNA, as determined by gel electrophoresis. Importantly, 2 and 10 kg/mol PEG conjugated to the 3'-sense strand of DsiRNA showed potent gene silencing activity in human neuroblastoma (SH-EP) cells, stably expressing eGFP, at both the mRNA and protein levels. Moreover, the 10 kg/mol PEG conjugates of the 3'-sense strand of DsiRNA were less immunogenic when compared with the unmodified DsiRNA, determined via an immune stimulation assay on human peripheral blood mononuclear cells.
Subject(s)
Green Fluorescent Proteins/genetics , Polyethylene Glycols/chemistry , RNA, Small Interfering/chemistry , Transfection/methods , Cell Line, Tumor , DEAD-box RNA Helicases/metabolism , Humans , Leukocytes, Mononuclear/immunology , Molecular Weight , Neuroblastoma/genetics , RNA Interference , RNA, Double-Stranded/genetics , RNA, Small Interfering/genetics , RNA, Small Interfering/metabolism , Ribonuclease III/metabolismABSTRACT
Biodegradable/bioeliminable, core-cross-linked, block co-polymer nanoparticles have been synthesized as a potential anti-tumour drug-delivery system. Methacrylate-modified poly(ethylene glycol)-b-poly(D,L-lactide) (PEG-b-PDLLA) composed of low-molecular-weight polymer blocks (<5 kg/mol) were synthesized by ring-opening polymerization and post-polymerization chemical modifications. Nanoparticles with a diameter of 110 ± 20 nm were formed from methacrylate-modified PEG(45)-b-PDLLA(41) in a THF/water mixture (1:3). The particles were then core-cross-linked using a new, highly acid-labile ketal cross-linker. The cross-linked particles had a hydrodynamic diameter of 104 ± 20 nm (in THF/water, 1:3), as determined by DLS. The particles in THF exhibited a similar hydrodynamic diameter. Doxorubicin as a model anti-tumour drug was loaded into the nanoparticles (25-31 wt%). The particles released 50% of the loaded drug slowly approximately in 2 days at pH 5.5 and in 5 days at pH 7.4. The particles degraded to bioeliminable polymer fragments (<40 kg/mol) after the hydrolysis of the ketal cross-links at pH 5.5 in seven days, as determined by GPC. Doxorubicin-loaded cross-linked particles (9.3 µM doxorubicin/2.5 µM polymer) inhibited the viability of human neuroblastoma SH-EP cells, whilst the particles without drug at the same concentration were non-toxic, as determined by an Alamar Blue assay. Flow cytometry experiments revealed that the doxorubicin-loaded cross-linked particles were taken up by SH-EP cells in quantities comparable with free doxorubicin. Overall the results support the value of the cross-linked particles for further investigation as a carrier for anti-tumour drugs.
